
CAS 784138-08-5
:Org-28611
CAS:Produto ControladoOrg-28611 is a synthetic cannabinoid that binds to the CB2 receptor. It has been shown to inhibit inflammatory pain in cell culture and also has anti-inflammatory and analgesic effects in animal models of chronic pain. Org-28611 is being investigated as a potential treatment for neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and multiple sclerosis. This drug is currently undergoing clinical trials in humans for the treatment of Parkinson's disease and Huntington's disease. Org-28611 does not bind to the CB1 receptor or stimulate it; instead, it acts as a selective agonist at the CB2 receptor. The drug was found to be well tolerated when administered orally at doses up to 500 mg/day for 28 days in healthy volunteers.
Pureza:Min. 95%
